ABVC — ABVC Biopharma Income Statement
0.000.00%
Last trade - 00:00
- $15.00m
- $16.07m
- $0.15m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.702 | 0.483 | 0.356 | 0.97 | 0.152 |
Cost of Revenue | |||||
Gross Profit | 0.682 | 0.464 | 0.351 | 0.683 | -0.15 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 4.16 | 9.95 | 12.1 | 16.2 | 8.37 |
Operating Profit | -3.46 | -9.47 | -11.7 | -15.2 | -8.22 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.01 | -10.8 | -11.2 | -15.5 | -10.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.93 | -10.6 | -12 | -16.3 | -10.9 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -3.64 | -9.79 | -12.8 | -16.4 | -10.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.64 | -9.79 | -12.8 | -16.4 | -10.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.08 | -4.65 | -5.12 | -5.16 | -2.43 |